PHILADELPHIA - Women pay an average of 40 percent more than men for minoxidil foams - a hair loss remedy most commonly known as Rogaine - according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania. The price difference appears despite the fact that the men's and women's version of the products - which are branded and marketed differently -- contain the same drug strength and inactive ingredients. JAMA Dermatology published the findings online today.
"Gender-based consumer price differences are well-documented, but we believe this is the first analysis comparing the pricing of medication along gender lines," said Jules Lipoff, MD, an assistant professor of Dermatology and the study's lead author.
An estimated 50 million men and 30 million women in America have androgentic alopecia - otherwise known as male-pattern or female-pattern baldness. With men, it usually presents as a receding hairline, while in women, it usually causes thinning of the hair. A recent study found the global market for treatments of this condition will reach $11.8 billion by the year 2024.
Minoxidil is one of the most common products currently on the market. Originally, the product contained a five percent solution for men and a two percent solution for women, and those products are still available in pharmacies. In 2014, the Food and Drug Administration approved the use of the five percent solution for women. There is now a version of the product sold to both men and women as a foam. Women apply it once daily, while men are directed to use it twice per day. All of the products involved in this research are sold over-the-counter.
Lipoff and his team looked at data from 24 different pharmacies across four states and compared them by retail price. In each case, they used the price of the largest container available by volume. When prices varied between different locations within the same chain, they used the average cost.
For the foam products containing five percent minoxidil, researchers found the cost was 40 percent higher per ounce (30 mL) for women than men.
"These are products with the exact same ingredients," Lipoff said. "They come in different amounts and packaging based on gender, so for the most part, women probably do not even realize they are paying more."
Lipoff says the justification could be that women will get more out of the product since they require fewer daily doses, or that there could be differences in the cost of product testing, approval, and marketing, but that still leaves women paying more per ounce.
"We recommend that our female patients buy the male version of the product, because it doesn't seem right to ask a woman to pay more when the products are, for all intents and purposes, identical."
Lipoff's team also compared the cost of women's two percent solution to men's five percent solution and found them to be virtually identical.
There is existing research to document gender-based consumer price differences. A 2015 report found women pay an average of 13 percent more than men on equivalent personal care products. But Lipoff said since most medications are not gender-specific, it's rare to have the opportunity to compare costs this way.
"We're just taking an objective look at the current costs," Lipoff said. "Still, we don't think it's right to charge different people different prices for the exact same drug."
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.